Regeneron Pharmaceuticals has agreed to supply the US Government with 1.4 million additional doses of its Covid-19 antibody cocktail, REGEN-COV, which is a combination of casirivimab and imdevimab. The new deal takes the total REGEN-COV doses purchased by the US to approximately three million. The company will supply the additional doses by 31 January 2022 at $2,100 per dose, placing the value of the latest agreement at $2.94bn.

German biopharma company Curevac plans to terminate manufacturing contracts with WACKER for the mRNA drug substance of its Covid-19 vaccine candidate, CVnCoV, and with Celonic for the production and formulation of the vaccine’s mRNA drug substance. The move is part of the company’s adjustment to the external European network for its mRNA product manufacturing. CureVac noted that the decision comes in response to the lowered short-term peak demand for vaccines after the first wave of Covid-19 vaccination initiatives and the related drop in the demand for CVnCoV. CureVac’s contracts with Rentschler Biopharma and Novartis for mRNA production and formulation are unaffected, the company said.

Emergent BioSolutions has signed a five-year development and manufacturing agreement for Providence Therapeutics’ mRNA Covid-19 vaccine candidate, PTX-COVID19-B. Next year, Emergent will produce tens of millions of doses of PTX-COVID19-B drug product and batches of the vaccine’s formulated bulk drug substance. The $90m agreement covers manufacturing services and studies to back supply chain activities, along with facility and equipment investments.